The Leuven-based company, which almost went under last year, wants to pay 10 million euros.
The Leuven-based biotech company Oxurion, which was on the verge of bankruptcy last year, has started exclusive negotiations to take an 80 percent stake in a French research company specializing in stem cell production for almost 10 million euros.
It announced this on Monday.
It is not known exactly which Contract Research Organisation (CRO) is involved. A CRO is a company that provides support to the pharmaceutical industry in the form of research services that are outsourced on a contract basis.
The deal, which both parties are now negotiating exclusively, values the research company in its entirety at 12.23 million euros.
The new CEO Pascal Ghoson already indicated in January that Oxurion would go on the acquisition path to create shareholder value,
